Supernus Pharmaceuticals Inc (NASDAQ:SUPN) — Market Cap & Net Worth
Market Cap & Net Worth: Supernus Pharmaceuticals Inc (SUPN)
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has a market capitalization of $2.53 Billion ($2.53 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5544 globally and #1774 in its home market, demonstrating a -2.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Supernus Pharmaceuticals Inc's stock price $43.58 by its total outstanding shares 58039721 (58.04 Million). Review how much debt does Supernus Pharmaceuticals Inc carry to assess the company's total debt and financial obligations.
Supernus Pharmaceuticals Inc Market Cap History: 2015 to 2026
Supernus Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $780.05 Million to $2.53 Billion (9.00% CAGR).
Index Memberships
Supernus Pharmaceuticals Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.10% | #131 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.01% | #607 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.15% | #84 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.65 Trillion | 0.15% | #256 of 602 |
Weight: Supernus Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Supernus Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Supernus Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.01x
Supernus Pharmaceuticals Inc's market cap is 4.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.47 Billion | $215.00 Million | $91.22 Million | 6.82x | 16.07x |
| 2017 | $2.31 Billion | $302.24 Million | $57.28 Million | 7.65x | 40.38x |
| 2018 | $1.93 Billion | $408.90 Million | $110.99 Million | 4.72x | 17.37x |
| 2019 | $1.38 Billion | $392.75 Million | $113.06 Million | 3.51x | 12.18x |
| 2020 | $1.46 Billion | $520.40 Million | $126.95 Million | 2.81x | 11.50x |
| 2021 | $1.69 Billion | $579.77 Million | $53.42 Million | 2.92x | 31.68x |
| 2022 | $2.07 Billion | $667.24 Million | $60.71 Million | 3.10x | 34.10x |
| 2023 | $1.68 Billion | $607.52 Million | $1.32 Million | 2.76x | 1276.34x |
| 2024 | $2.10 Billion | $661.82 Million | $73.86 Million | 3.17x | 28.41x |
| 2025 | $2.88 Billion | $718.95 Million | -$38.55 Million | 4.01x | N/A |
Competitor Companies of SUPN by Market Capitalization
Companies near Supernus Pharmaceuticals Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Supernus Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Supernus Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Supernus Pharmaceuticals Inc's market cap moved from $780.05 Million to $ 2.53 Billion, with a yearly change of 9.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.53 Billion | -12.31% |
| 2025 | $2.88 Billion | +37.44% |
| 2024 | $2.10 Billion | +24.95% |
| 2023 | $1.68 Billion | -18.87% |
| 2022 | $2.07 Billion | +22.33% |
| 2021 | $1.69 Billion | +15.90% |
| 2020 | $1.46 Billion | +6.07% |
| 2019 | $1.38 Billion | -28.60% |
| 2018 | $1.93 Billion | -16.64% |
| 2017 | $2.31 Billion | +57.82% |
| 2016 | $1.47 Billion | +87.87% |
| 2015 | $780.05 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Supernus Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.53 Billion USD |
| MoneyControl | $2.53 Billion USD |
| MarketWatch | $2.53 Billion USD |
| marketcap.company | $2.53 Billion USD |
| Reuters | $2.53 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with P… Read more